지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2015.12
- 수록면
- 106 - 113 (8page)
이용수
초록· 키워드
오류제보하기
Purpose: The aim of this study is to evaluate the prognostic factors of the group who received neoadjuvant chemotherapy with a taxane-anthracycline combination regimen.
Methods: We retrospectively analyzed for locally advanced breast cancer patients who received neoadjuvant chemotherapy with adjuvant extension with taxane-anthracycline combination regimen. 101 patients received neoadjuvant chemotherapy with docetaxel and doxorubicin, 46 patients received with epirubicin and paclitaxel. After curative surgery, adjuvant chemotherapy with the same regimen was performed. The adjuvant chemotherapy regimen was adjusted when the response to neoadjuvant chemotherapy was in disease progression.
Results: The disease free survival is 78% after 5 years and 71% after 10 years for good response group; the disease free survival is 23% in 5 years and 23% in 10 years for the no response group (P<0.001). The overall survival is 93% after 5 years and 90% after 10 years for the good response group; the overall survival is 47% after 5 years and 38% after 10 years for the no response group (P<0.001). 13 patients of 17 patients who to be appeared in complete response were triple negative for breast cancer.
Conclusion: In order to predict an oncologic outcome from locally advanced breast cancer patients who are treated with neoadjuvant chemotherapy with taxane-anthracycline based regimen, we can use pathologic complete response, an early response to neoadjuvant chemotherapy.
Methods: We retrospectively analyzed for locally advanced breast cancer patients who received neoadjuvant chemotherapy with adjuvant extension with taxane-anthracycline combination regimen. 101 patients received neoadjuvant chemotherapy with docetaxel and doxorubicin, 46 patients received with epirubicin and paclitaxel. After curative surgery, adjuvant chemotherapy with the same regimen was performed. The adjuvant chemotherapy regimen was adjusted when the response to neoadjuvant chemotherapy was in disease progression.
Results: The disease free survival is 78% after 5 years and 71% after 10 years for good response group; the disease free survival is 23% in 5 years and 23% in 10 years for the no response group (P<0.001). The overall survival is 93% after 5 years and 90% after 10 years for the good response group; the overall survival is 47% after 5 years and 38% after 10 years for the no response group (P<0.001). 13 patients of 17 patients who to be appeared in complete response were triple negative for breast cancer.
Conclusion: In order to predict an oncologic outcome from locally advanced breast cancer patients who are treated with neoadjuvant chemotherapy with taxane-anthracycline based regimen, we can use pathologic complete response, an early response to neoadjuvant chemotherapy.
목차
INTRODUCTION
METHODS
RESULTS
DISCUSSION
REFERENCES
참고문헌 (0)
참고문헌 신청함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Taxane-Based Regimens as Adjuvant Treatment for Breast Cancer: a Retrospective Study in Egyptian Cancer Patients
Asian Pacific journal of cancer prevention : APJCP
2015 .01
-
Predictive and Prognostic Roles of Pathological Indicators for Patients with Breast Cancer on Neoadjuvant Chemotherapy
Journal of Breast Cancer
2019 .01
-
Role of Neoadjuvant Chemotherapy in the Management of Advanced Ovarian Cancer
Asian Pacific journal of cancer prevention : APJCP
2015 .01
-
Selection of Neoadjuvant Chemotherapy Regimen and Role of Additional Adjuvant Therapy
대한외과학회 학술대회 초록집
2021 .11
-
Selection of the Best Candidate and Optimal Regimen for Neoadjuvant Chemotherapy
대한외과학회 학술대회 초록집
2020 .11
-
The Role of Neoadjuvant Chemotherapy in Patients with ER Positive and HER2 Negative Breast Cancer
대한외과학회 학술대회 초록집
2018 .11
-
Evaluation of the Survival Benefit of Different Chemotherapy Regimens in Patients with T1-2N0 Triple-Negative Breast Cancer
Journal of Breast Cancer
2015 .01
-
Radiologic complete response after neoadjuvant chemotherapy in advanced breast cancer can predict survival outcome, but not pathologic complete response
대한외과학회 학술대회 초록집
2019 .10
-
[Breast] MRI in the Prediction of Pathological Complete Response in Breast Cancer Patients after Neoadjuvant Chemotherapy
대한외과학회 학술대회 초록집
2022 .11
-
Radiological response pattern and patient survival in patients undergoing neoadjuvant chemotherapy
대한외과학회 학술대회 초록집
2019 .10
-
The Prognosis and the Role of Adjuvant Chemotherapy for Node-Positive Bladder Cancer Treated with Neoadjuvant Chemotherapy Followed by Surgery
Cancer Research and Treatment
2022 .01
-
선행항암화학요법을 받는 유방암 환자의 불안, 불확실성, 암 대처가 삶의 질에 미치는 영향
Asian Oncology Nursing
2022 .03
-
전이성 유방암 환자에서 Cisplatin과 Etoposide 항암화학요법을 이용한 치료
Journal of Breast Disease
2017 .12
-
Options and Outcomes of Neoadjuvant Chemotherapy
대한외과학회 학술대회 초록집
2021 .11
-
Tumor Elasticity and Clinicopathologic Factors Affecting Neoadjuvant Chemotherapy Response in Breast Cancer Patients
대한외과학회 학술대회 초록집
2020 .11
-
Progression during Neoadjuvant Chemotherapy for Locally Advanced Breast Cancer Is a High Risk of Recurrence and Mortality
대한외과학회 학술대회 초록집
2020 .11
-
Neoadjuvant Chemotherapy versus Adjuvant Chemotherapy in Breast Cancer Patients: Analysis of Breast Conserving Rate and De-escalation of Axillary Surgery in 5141 Korean Women
대한외과학회 학술대회 초록집
2020 .11
-
Comparing Role of Two Chemotherapy Regimens, CMF and Anthracycline-Based, on Breast Cancer Survival in the Eastern Mediterranean Region and Asia by Multivariate Mixed Effects Models: a Meta-Analysis
Asian Pacific journal of cancer prevention : APJCP
2015 .01
-
Comparison of Clinical Outcomes of Breast Cancer Patients Who Had more than 10 Positive Axillary Lymph Nodes Treated With Anthracycline or Taxane Based Chemotherapy
대한외과학회 학술대회 초록집
2020 .11
-
Safety Analysis of Adjuvant Chemotherapy with Docetaxel Administered with or without Anthracyclines to Early Stage Breast Cancer Patients: Combined Results from the Asia-Pacific Breast Initiatives I and II
Asian Pacific journal of cancer prevention : APJCP
2016 .01
이 논문의 저자 정보
최근 본 자료
댓글(0)
0
UCI(KEPA) : I410-ECN-0101-2016-513-002430327